Pfizer (PFE) is ending a late-stage trial of its once-daily GLP-1 pill, Danuglipron, after a participant experienced a liver ...

Market OverviewThe Global Osteoarthritis Pain Drugs Market is valued at USD 10.32 Billion in 2023 and is projected to reach a value of USD 17.96 Billion by 2032 at a CAGR (Compound Annual Growth Rate) ...

The LATAM pain management drugs market was valued at $2,683.82 million in 2019, and is projected to reach $3,383.20 million by 2027, registering a CAGR of 3.5% from 2020 to 2027. The length of pain ...

The moves, announced Monday in the Federal Register, are a precursor to imposing tariffs and threaten to broaden the president’s sweeping US trade war ...

A groundbreaking study published in the International Journal of Cardiovascular Research & Innovation reveals alarming long-term heart risks linked to COVID-19 mRNA vaccines, challenging official ...

Pfizer has ceased development of its oral GLP-1 weight loss drug candidate, danuglipron, after a study participant ...

Pfizer (PFE) stock slips as the company halts development of danuglipron for weight loss due to liver injury concerns. Read ...

The two obesity market leaders, with their blockbuster injectables, have left room for an oral, or pill, market to be a new meaningful target for newer players, according to investors. Lilly is the ...

Pfizer has discontinued its experimental weight-loss pill danuglipron after a trial patient experienced potential ...

Capping more than two years of stock-gyrating drama, Pfizer said Monday that it would stop development of danuglipron, its ...

Find insight on Pfizer, Roche and more in the latest Market Talks covering the Health Care sector.

The implications for Eli Lilly and Novo Nordisk seem pretty clear: The immediate removal of a rival for the massive revenues ...